CareMetx Names Kurt Brumme Chief Executive
The Bethesda-based patient access provider has named its former chief financial officer to lead the company following its acquisition of Cencora's U.S. patient services business.
Updated on Nov. 3, 2026 in Healthcare
CareMetx's Board of Managers named Kurt Brumme Chief Executive Officer, succeeding the company's prior leadership. Brumme joined CareMetx as Chief Financial Officer in 2025 and led its financial strategy and corporate development efforts.
Why it matters
The appointment places a finance executive at the helm of a company that supports more than 300 pharmaceutical brands with patient access and pharmacy solutions. It comes alongside CareMetx's acquisition of Cencora's U.S. patient services and free goods pharmacy business.
CareMetx, founded in 2011, supports more than 300 pharmaceutical brands, and new CEO Kurt Brumme brings more than 20 years of healthcare and investing experience. The financial terms of the Cencora acquisition and its effect on revenue were not disclosed.
The players
CareMetx
CareMetx is a Bethesda, Maryland-based provider of technology-enabled patient access and pharmacy solutions to pharmaceutical manufacturers.
Kurt Brumme
Kurt Brumme is a healthcare and investing executive with more than 20 years of experience who previously served as CareMetx's Chief Financial Officer.
Greg Morris
Greg Morris is CareMetx's President and Chief Strategy Officer, overseeing the company's strategy and commercial efforts.
The details
CareMetx's Board of Managers selected Kurt Brumme, who joined the company as CFO in 2025 and led its financial strategy and corporate development, as CEO. Greg Morris, the company's President and Chief Strategy Officer, will continue to lead its strategy and commercial efforts.
Timeline
2011: CareMetx is founded.
2025: Brumme joins CareMetx as Chief Financial Officer.
November 3, 2026: CareMetx announces Brumme as CEO.
Market Landscape
The acquisition of Cencora's U.S. patient services and free goods pharmacy business extends the trend of pharmaceutical manufacturers outsourcing patient access and free goods programs to specialized third-party providers. CareMetx's expansion strengthens its position serving the more than 300 brands it already supports.
For patients taking medications supported by CareMetx, the company's patient access and free goods programs govern how they obtain therapies. Leadership changes and the Cencora acquisition may affect the administration of those programs, though the source does not detail any immediate changes.
The takeaway
Leadership transitions at patient access providers can signal shifts in how pharmaceutical manufacturers deliver therapies to patients. Readers tracking healthcare services should watch how CareMetx integrates the Cencora business under its new CEO.
Further reading
Explore more healthcare business news from the Bethesda area.
Source note: This article includes information reported by The Manila times.
